Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
1–6
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed participation in trial F13CD-3760 (NCT01230021)
You may not be if
Known or suspected hypersensitivity to trial product or related products
Known history of development of inhibitors against FXIII (factor XIII)
Hereditary or acquired coagulation disorder other than FXIII congenital deficiency
Platelet count (thrombocytes) less than 50X10e9 / L
Previous history of autoimmune disorder involving autoantibodies e.g., systemic lupus erythematosus
Previous history of arterial or venous thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis
Any disease or condition which, judged by the trial physician, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome including renal and/or liver dysfunction